Accès ouvert déclaré
2023
article
Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)
Alexandra Griessbach, Frédérique Chammartin, Irène A. Abela, Patrizia Amico, Marcel Stoeckle, Anna Eichenberger, Barbara Hasse, Dominique L. Braun, Macé M. Schuurmans, Thomas F. Müller, Michael Tamm, Annette Audigé, Nicolas J. Mueller, Andri Rauch, Huldrych F. Günthard, Michael Koller, Alexandra Trkola, Selina Epp, Alain Amstutz, Christof Schönenberger, Ala Taji Heravi, Matthaios Papadimitriou‐Olivgeris, Alessio Casutt, Oriol Manuel, Katharina Kusejko, Heiner C. Bucher, Matthias Briel, Benjamin Speich, Karoline Aebi‐Popp, A Anagnostopoulos, Manuel Battegay, Enos Bernasconi, Braun Dl, Bucher Hc, Alexandra Calmy, Matthias Cavassini, Angela Ciuffi, G Dollenmaier, Matthias Egger, Luigia Elzi, Jan Fehr, Jacques Fellay, Hansjakob Furrer, Fux Ca, Anna Hachfeld, David Haerry, Hirsch Hh, Matthias Hoffmann, Irène Hösli, Michael Huber, David Jackson‐Perry, Kahlert CR, Laurent Kaiser, Olivia Keiser, Thomas Klimkait, Roger D. Kouyos, Helen Kovari, Niklaus Daniel Labhardt, Karoline Leuzinger, Begoña Martínez de Tejada, Catia Marzolini, Metzner KJ, N Müller, Johannes Nemeth, Dunja Nicca, Julia Notter, P Paioni, G Pantaleo, Matthieu Perreau, Luisa Salazar‐Vizcaya, Patrick Schmid, Roberto F. Speck, M Stöckle, Philip Tarr, Gilles Wandeler, Maja Weisser, Sabine Yerly, John‐David Aubert, Vanessa Banz, Sonja Beckmann, Guido Beldi, Christoph Berger, Ekaterine Berishvili, Annalisa Berzigotti, Isabelle Binet, Pierre–Yves Bochud, Sanda Branca, Anne Cairoli, Yves Chalandon, Sabina De Geest, Olivier de Rougemont, Sophie de Seigneux, Michael Dickenmann, Joëlle Lynn Dreifuss, Michel A. Duchosal, Thomas Fehr, Sylvie Ferrari-Lacraz, Christian Garzoni, Déla Golshayan, Nicolas Goossens, Fadi Haidar, Jörg Halter, Dominik Heim, Christoph Hess, Sven Hillinger, Hans H. Hirsch, Patricia Hirt, Linard Hoessly, Günther F.L. Hofbauer, Uyen Huynh‐Do, Franz Immer, Bettina Laesser, Frédéric Lamoth, Roger Lehmann, Alexander Leichtle, Hans‐Peter Marti, Michele Martinelli, Valérie A. McLin, Katell Mellac, Aurélia Merçay, Karin Mettler, Ulrike Müller-Arndt, Beat Müllhaupt, Mirjam Nägeli, Graziano Oldani, Manuel Pascual, Jakob Passweg, Rosemarie Pazeller, Klara M. Posfay‐Barbe, Juliane Rick, Anne Rosselet, Simona Rossi, Silvia Rothlin, Frank Ruschitzka, Stefan Schaub, Alexandra Scherrer, Aurelia Schnyder, Simon Schwab, Thierry Sengstag, Federico Simonetta, Susanne Stampf, Jürg Steiger, Guido Stirnimann, Ueli Stürzinger, Christian van Delden, Jean-Pierre Venetz, Jean Villard, Julien Vionnet, Madeleine Wick, Markus J. Wilhelm, Patrick Yerly
4Citations signalées — pas une note de qualité
11Institutions déclarées
2Pays d’affiliation déclarés
Résumé fourni par la source
Background: After basic immunization with 2 mRNA SARS-CoV-2 vaccine doses, only a small proportion of patients who are severely immunocompromised generate a sufficient antibody response. Hence, we assessed the additional benefit of a third SARS-CoV-2 vaccine in patients with different levels of immunosuppression. Methods: In this observational extension of the COVERALL trial (Corona Vaccine Trial Platform), we recruited patients from the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study (ie, lung and kidney transplant recipients). We collected blood samples before and 8 weeks after the third SARS-CoV-2 vaccination with either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech). The primary outcome was the proportion of participants showing an antibody response (Elecsys Anti-SARS-CoV-2 S test; threshold ≥100 U/mL) 8 weeks after the third SARS-CoV-2 vaccination. We also compared the proportion of patients who reached the primary outcome from basic immunization (the first and second vaccines) to the third vaccination. Results: Nearly all participants (97.2% [95% CI, 95.9%-98.6%], 564/580) had an antibody response. This response was comparable between mRNA-1273 (96.1% [95% CI, 93.7%-98.6%], 245/255) and BNT162b2 (98.2% [95% CI, 96.7%-99.6%], 319/325). Stratification by cohort showed that 99.8% (502/503) of people living with HIV and 80.5% (62/77) of recipients of solid organ transplants achieved the primary endpoint. The proportion of patients with an antibody response in solid organ transplant recipients improved from the second vaccination (22.7%, 15/66) to the third (80.5%, 62/77). Conclusions: NCT04805125 (ClinicalTrials.gov).
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)
- Date Crossref
- 01/11/2023
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.
Institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Sujets associés
SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesHeparin-Induced Thrombocytopenia and Thrombosis